Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02654990
Title Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Acronym PANORAMA_3
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS

Facility Status City State Zip Country Details
Novartis Investigative Site Fayetteville Arkansas 72703 United States Details
Novartis Investigative Site Los Angeles California 90017 United States Details
Novartis Investigative Site Fort Collins Colorado 80528 United States Details
Novartis Investigative Site Gainesville Florida 32608 United States Details
Novartis Investigative Site Atlanta Georgia 30322 United States Details
Novartis Investigative Site Louisville Kentucky 40202 United States Details
Novartis Investigative Site Boston Massachusetts 02215 United States Details
Novartis Investigative Site Lake Success New York 11042 United States Details
Novartis Investigative Site Morgantown West Virginia 26506 United States Details
Novartis Investigative Site Prahran Victoria 3181 Australia Details
Novartis Investigative Site Hasselt 3500 Belgium Details
Novartis Investigative Site Barretos Sao Paulo 14784 400 Brazil Details
Novartis Investigative Site Sao Paulo SP 04537 081 Brazil Details
Novartis Investigative Site Sao Paulo 05403-000 Brazil Details
Novartis Investigative Site Edmonton Alberta T6G 1Z2 Canada Details
Novartis Investigative Site Kitchener Ontario N2G 1G3 Canada Details
Novartis Investigative Site Ostrava Poruba Czech Republic 708 52 Czechia Details
Novartis Investigative Site Praha 12808 Czechia Details
Novartis Investigative Site Bayonne Bayonne Cedex 64109 France Details
Novartis Investigative Site Avignon Cedex 9 84902 France Details
Novartis Investigative Site Grenoble 38043 France Details
Novartis Investigative Site La Roche sur Yon Cedex 85295 France Details
Novartis Investigative Site Lille 59037 France Details
Novartis Investigative Site Metz 57000 France Details
Novartis Investigative Site Nantes Cedex 1 44093 France Details
Novartis Investigative Site Paris 75231 France Details
Novartis Investigative Site Pessac 33604 France Details
Novartis Investigative Site Bad Saarow 15526 Germany Details
Novartis Investigative Site Bayreuth 95445 Germany Details
Novartis Investigative Site Darmstadt 64287 Germany Details
Novartis Investigative Site Dresden 01307 Germany Details
Novartis Investigative Site Halle Saale 06120 Germany Details
Novartis Investigative Site Hamburg 22763 Germany Details
Novartis Investigative Site Kiel 24105 Germany Details
Novartis Investigative Site Leipzig 04103 Germany Details
Novartis Investigative Site Athens 115 27 Greece Details
Novartis Investigative Site Athens 115 28 Greece Details
Novartis Investigative Site Patras 265 00 Greece Details
Novartis Investigative Site Debrecen HUN 4032 Hungary Details
Novartis Investigative Site Budapest 1097 Hungary Details
Novartis Investigative Site Kaposvar 7400 Hungary Details
Novartis Investigative Site Nyiregyhaza 4400 Hungary Details
Novartis Investigative Site Roma RM 00161 Italy Details
Novartis Investigative Site Rimini RN 47900 Italy Details
Novartis Investigative Site Hwasun 58128 Korea, Republic of Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Beirut 166830 Lebanon Details
Novartis Investigative Site Beirut Lebanon Details
Novartis Investigative Site Sidon 652 Lebanon Details
VUmc, Hematology, PK2 BR012 Amsterdam 1081 HV Netherlands Details
Albert Schweitzer ziekenhuis, Hematology Dordrecht 3318 AT Netherlands Details
Novartis Investigative Site Oslo NO 0450 Norway Details
Novartis Investigative Site Lublin 20 090 Poland Details
Novartis Investigative Site Torun 87 100 Poland Details
Novartis Investigative Site Warszawa 02 106 Poland Details
Novartis Investigative Site Warszawa 02 776 Poland Details
Novartis Investigative Site Wroclaw 50 367 Poland Details
Novartis Investigative Site Braga 4710243 Portugal Details
Novartis Investigative Site Porto 4200-072 Portugal Details
Novartis Investigative Site Saint Petersburg 191024 Russian Federation Details
Novartis Investigative Site Saratov 410012 Russian Federation Details
Novartis Investigative Site Malaga Andalucia 29010 Spain Details
Novartis Investigative Site Salamanca Castilla Y Leon 37007 Spain Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Barcelona Catalunya 08036 Spain Details
Novartis Investigative Site L'Hospitalet De Llobregat Catalunya 08907 Spain Details
Novartis Investigative Site La Laguna Santa Cruz De Tenerife 38320 Spain Details
Novartis Investigative Site Madrid 28006 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site Zaragoza 50009 Spain Details
Novartis Investigative Site Lulea SE 971 80 Sweden Details
Novartis Investigative Site Lund SE-221 85 Sweden Details
Novartis Investigative Site Uppsala SE-751 85 Sweden Details
Novartis Investigative Site Mueang Nonthaburi Muang 40002 Thailand Details
Novartis Investigative Site Bangkok 10330 Thailand Details
Novartis Investigative Site Chiang Mai 50200 Thailand Details
Novartis Investigative Site Ankara 06100 Turkey Details
Novartis Investigative Site Istanbul 34899 Turkey Details
Novartis Investigative Site Izmir 35340 Turkey Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field